RecruitingOBSERVATIONAL

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

This study focuses on people in the UK who have a type of blood cancer called multiple myeloma that has come back or hasn't responded to earlier treatments. It specifically looks at two newer treatments, teclistamab and talquetamab, when they are used in regular patient care, rather than as part of a formal clinical trial setting. The main goal is to understand how these treatments are working for patients in everyday practice. This includes looking at how people get on with the treatments and their overall health outcomes. By gathering this information, researchers hope to get a clearer picture of these medicines' effectiveness and how they are used in the real world for myeloma patients.

At a glance

Status

Recruiting

Sponsor

Janssen-Cilag Ltd.

Enrolment target

900

Start

18 Dec 2023

Estimated completion

24 Sep 2026

Relapsed/Refractory Multiple Myeloma (RRMM)

What is this study about?

This study is about a type of blood cancer called multiple myeloma. Sometimes, after treatment, this cancer can come back or stop responding to the medicines given. When this happens, it's called 'relapsed/refractory multiple myeloma' (often shortened to RRMM).

The study is interested in two relatively new treatments, teclistamab and talquetamab. These medicines work by helping your body's immune system fight the cancer. The unique thing about this study is that it's looking at how these treatments work for people who have received them as part of their regular care, not as part of a super-controlled clinical trial.

By gathering information from many patients who have already received these medicines, researchers hope to get a better understanding of how well they work in a real-world setting. This kind of information is very helpful for doctors and other patients because it shows how the treatments are performing in everyday situations.

Key takeaways

This study focuses on real-world results of teclistamab and talquetamab.
It's for people with multiple myeloma that has returned or resisted previous treatments.
Data will be collected from existing medical records, not from new treatments.
The aim is to understand how these medicines perform in everyday patient care.
Your privacy is important, and all information will be handled confidentially.

Who may be eligible?

To be part of this study, you must have been diagnosed with multiple myeloma. You would also need to have received at least one dose of either teclistamab or talquetamab as part of your standard medical care, not as part of a specific trial where the treatment was being tested.

The study is looking at patients who started teclistamab at different times: either before the end of 2022, or between January 2023 and December 2024, or between January and December 2025. For talquetamab, they are looking at patients who started treatment before the end of 2023. If you received both treatments, you could be included in both groups. If you received teclistamab or talquetamab as part of another specific clinical study, you would not be able to join this particular study. Also, if you got teclistamab through a special early access program from the company, you might not be eligible for certain parts of this study.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Do I have a confirmed diagnosis of multiple myeloma?
Have I received treatment with teclistamab or talquetamab?
Did I receive this treatment as part of my routine care, not as a test drug in a research study?
Am I at least 18 years old?

Answer every question to see your result.

What does participation involve?

If you are eligible and agree to take part, the study will mainly involve collecting information about your health and treatment from your existing medical records. This means you likely won't need extra visits or new medical tests specifically for this study. The researchers will look at details about your multiple myeloma, the doses of teclistamab or talquetamab you received, how long you took it, and how your health has been since starting treatment. The total duration of your participation would depend on how long your treatment and follow-up records are available.

Potential risks and benefits

Since this study primarily involves reviewing existing medical records, there are very few direct risks to you. Your medical information will be kept private and handled carefully. A potential benefit is that the information gathered from your treatment experience, combined with many others, could help doctors and researchers better understand how these medicines work in the real world. This could lead to improved care for future patients with multiple myeloma. Remember, you would always have the right to withdraw your consent for your medical information to be used in the study at any time without affecting your medical care.

Locations (68)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Aalborg Sygehus Syd
Verified postcode
Aalborg, Denmark· Recruiting
Aarhus Universitetshospital
Verified postcode
Aarhus N, Denmark· Completed
Rigshospitalet
Verified postcode
Copenhagen, Denmark· Completed
Odense University Hospital
Verified postcode
Odense, Denmark· Completed
Sygehus Lillebælt, Vejle
Verified postcode
Vejle, Denmark· Recruiting
Hopital Albert Calmette - CHU Lille
Verified postcode
Lille, France· Recruiting
Institut Paoli Calmettes
Verified postcode
Marseille, France· Completed
CHU de Nantes hotel Dieu
Verified postcode
Nantes, France· Recruiting
Hopital Saint Louis
Verified postcode
Paris, France· Completed
Institut Universitaire du Cancer Toulouse Oncopole
Verified postcode
Toulouse, France· Recruiting
CHRU de Nancy - Hopitaux de Brabois
Verified postcode
Vandœuvre-lès-Nancy, France· Completed
Klinikum Chemnitz gGmbH
Verified postcode
Chemnitz, Germany· Completed

Common questions

What is multiple myeloma?

Multiple myeloma is a type of cancer that affects white blood cells called plasma cells, found in the bone marrow.

What does 'relapsed/refractory' mean?

It means the cancer has come back after treatment, or has not responded to previous treatments.

What are teclistamab and talquetamab?

These are newer medicines designed to help your immune system fight multiple myeloma cells.

Will I have to take new medicine if I join?

No, this study only looks at information from people who have already taken these medicines as part of their regular care. You won't be given any new medicine for the study itself.

Is this a clinical trial where new treatments are tested?

No, this study is about observing how treatments already being used are working in standard medical practice, not testing a new drug.

How to find out more

Study Contact

participate-in-this-study1@its.jnj.com 844-434-4210 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.